Company profile for Ichnos Glenmark Innovation

NEW Drugs in Dev: 2
PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

IGInnovate is a biotechnology company dedicated to advancing healthcare through innovative solutions in drug development and biotechnology. Our mission is to harness cutting-edge technology and scientific expertise to create transformative therapies that address unmet medical needs. We focus on developing novel therapeutics and diagnostic tools that improve patient outcomes and enhance the quality of life. At IGInnovate, we ar...
IGInnovate is a biotechnology company dedicated to advancing healthcare through innovative solutions in drug development and biotechnology. Our mission is to harness cutting-edge technology and scientific expertise to create transformative therapies that address unmet medical needs. We focus on developing novel therapeutics and diagnostic tools that improve patient outcomes and enhance the quality of life. At IGInnovate, we are committed to driving innovation in the life sciences industry, fostering collaboration, and delivering impactful solutions that contribute to a healthier future.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1 World Trade Center, 76th Floor, Suite D, New York, NY 10007, United States
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.indianpharmapost.com/news/ichnos-glenmark-innovation-receives-upfront-payment-of-700-million-from-abbvie-17752

INDPHARMAPOST
10 Sep 2025

https://news.abbvie.com/2025-07-10-AbbVie-and-Ichnos-Glenmark-Innovation-IGI-Announce-Exclusive-Global-Licensing-Agreement-for-ISB-2001,-a-First-in-Class-CD38xBCMAxCD3-Trispecific-Antibody

PRESS RELEASE
12 Jul 2025

https://www.globenewswire.com/news-release/2025/06/02/3091923/0/en/Full-Dose-Escalation-Data-Show-Continued-High-Response-Rates-and-Favorable-Safety-Profile-of-ISB-2001-a-First-in-Class-BCMA-CD38-CD3-Trispecific-Antibody-for-the-Treatment-of-Relap.html

GLOBENEWSWIRE
02 Jun 2025

https://www.globenewswire.com/news-release/2025/05/05/3073932/0/en/Ichnos-Glenmark-Innovation-IGI-Receives-U-S-FDA-Fast-Track-Designation-for-ISB-2001-for-Relapsed-Refractory-Multiple-Myeloma.html

GLOBENEWSWIRE
05 May 2025

https://www.globenewswire.com/news-release/2024/11/05/2974962/0/en/Ichnos-Glenmark-Innovation-IGI-Announces-First-Presentation-of-Data-from-Phase-1-Study-of-the-Trispecific-ISB-2001-in-Relapsed-Refractory-Multiple-Myeloma-r-rMM-at-Upcoming-ASH-Ann.html

GLOBENEWSWIRE
05 Nov 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty